• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, August 24, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Localized immunotherapy new possibility to treat bladder cancer

Bioengineer by Bioengineer
December 8, 2016
in Science News
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Antibody-based immunotherapy is a new promising method to treat cancer. Unfortunately, today's treatments can result in adverse side effects. New findings from Uppsala University show an alternative way to administer the therapy, which has the same effect on the tumour but less impact other parts of the body.

In antibody-based immunotherapy drugs are used to stimulate the body's own immune cells to attack and destroy the tumour cells. This method is presently used to treat certain types of metastasised cancer, such as melanoma and bladder cancer. However, a disadvantage of the therapy is that the drug is injected in the blood, which will lead to an exposure of the whole body and thereby possible adverse events.

An alternative strategy would be to administer the drug directly in or close to the tumour, provided that this still leads to the desired immune cell stimulation. In the present study a group of researchers, led by Sara Mangsbo at Department of Immunology, Genetics and Pathology, IGP, has demonstrated that a local immune activation in the tumour area had the same tumour inhibiting capacity as when the drug was delivered in the blood.

'We found that the therapy that we tested in a model system of bladder cancer could stimulate the immune cells to find and attack the cancer cells, even if it was administered locally. These results are very promising since they indicate that it's not necessary to activate the body's whole immune system, but only the one that is relevant in the tumour. This way adverse events caused by the drug can be reduced,' says Sara Mangsbo.

In the study immune activation was achieved by administering blocking antibodies close to the tumour. The results complement the researcher's previous findings where they found that a direct immune stimulatory antibody had superior anti-tumour capacity when used locally at the tumour, as compared to after injection into the blood.

The hope is also that the immune cells, not the drug itself, can find potential metastases and eliminate them. To understand if and how this is happening, further research is required. The present results are based on studies in mice and to determine if drug administration to the tumour results in fewer adverse events in patients, as compared to injections into the blood stream, clinical studies are also needed.

###

The study is a collaboration with researchers in Lund and in Canada and was recently published in European Journal of Immunology.

Luuk van Hooren et al, Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer, European Journal of Immunology november 2016, http://onlinelibrary.wiley.com/doi/10.1002/eji.201646583/abstract

More information:

Sara Mangsbo, associated Professor and researcher at Department of Immunology, Genetics and Pathology (IGP), Uppsala university, [email protected], tel 070-425 08 78

Media Contact

Sara Mangsbo
[email protected]
46-704-250-878
@UU_University

http://www.uu.se

############

Story Source: Materials provided by Scienmag

Share12Tweet8Share2ShareShareShare2

Related Posts

Nature’s Remedies: Green Chemistry for Prostate Health

Nature’s Remedies: Green Chemistry for Prostate Health

August 24, 2025
Equity in Ethiopia’s HIV/AIDS Policy: A Content Analysis

Equity in Ethiopia’s HIV/AIDS Policy: A Content Analysis

August 24, 2025

Barriers to Patient-Reported Outcomes in Rheumatoid Arthritis

August 24, 2025

Snake Secretions Repel and Poison Ants

August 24, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Molecules in Focus: Capturing the Timeless Dance of Particles

    141 shares
    Share 56 Tweet 35
  • Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    132 shares
    Share 53 Tweet 33
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    115 shares
    Share 46 Tweet 29
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    81 shares
    Share 32 Tweet 20

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Nature’s Remedies: Green Chemistry for Prostate Health

Equity in Ethiopia’s HIV/AIDS Policy: A Content Analysis

Barriers to Patient-Reported Outcomes in Rheumatoid Arthritis

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.